Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.
Bram VerstocktNurulamin M NoorUrko M MarigortaPolychronis PavlidisParakkal DeepakRyan C Ungaronull nullPublished in: Journal of Crohn's & colitis (2022)
Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.
Keyphrases
- ulcerative colitis
- end stage renal disease
- healthcare
- ejection fraction
- machine learning
- chronic kidney disease
- clinical trial
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- electronic health record
- mesenchymal stem cells
- risk assessment
- big data
- phase iii
- bone marrow
- patient reported outcomes
- smoking cessation
- combination therapy
- open label
- double blind
- placebo controlled
- nk cells